Neuphoria Therapeutics (NEUP) Common Equity (2020 - 2026)

Neuphoria Therapeutics (NEUP) has reported Common Equity for 7 consecutive years, with $29.4 million the latest figure, recorded in Q1 2026.

• On a quarterly basis, Common Equity rose 13.18% year-over-year to $29.4 million in Q1 2026; TTM through Mar 2026 was $29.4 million, a 13.18% increase from a year earlier, with the FY2025 full-year figure at $19.0 million, up 8.65% from the prior year.
• Common Equity was $29.4 million for Q1 2026 at Neuphoria Therapeutics, down from $29.7 million in the prior quarter.
• Over five years, Common Equity peaked at $40.8 million in Q2 2022 and troughed at $12.5 million in Q3 2025.
• A 5-year average of $21.7 million and a median of $19.0 million in 2025 frame the typical range for Common Equity.
• Across the five-year window, Common Equity tumbled 45.65% in 2023 and surged 116.04% in 2025, its largest moves.
• Over 5 years, Common Equity stood at $40.8 million in 2022, then slumped by 52.17% to $19.5 million in 2023, then declined by 29.49% to $13.7 million in 2024, then surged by 116.04% to $29.7 million in 2025, then fell by 0.93% to $29.4 million in 2026.
• The last three Common Equity figures came in at $29.4 million (Q1 2026), $29.7 million (Q4 2025), and $12.5 million (Q3 2025), per Business Quant data.